An increased risk of new-onset diabetes mellitus has been recently reported for statin
therapy, and experimental studies have shown reduced glucose-stimulated insulin secretion …

Human organic anion transporting polypeptide 3A1 (OATP3A1) is predominately expressed
in the heart. The ability of OATP3A1 to transport statins into cardiomyocytes is unknown …

3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors (statins) are prominent
cholesterol lowering maintenance drugs that have been previously implicated in altering …

The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor pravastatin has been
reported to have a beneficial effect on reducing the new onset of diabetes as well as …

Organic anion transporting polypeptide (Oatp) 1a/1b knockout and OATP1B1 and-1B3
humanized mouse models are promising tools for studying the roles of these transporters in …

Response to statin therapy is often unpredictable because of variability in metabolism and
transport. In the recently created organic anion transporting‐polypeptide 1b2 …

As patients with type 2 diabetes receiving oral antidiabetic drugs are often concomitantly
treated with other drugs, they are of increased risk for drug interactions. Drugs have to be …

Cytotoxicity of a compound is determined by the intracellular concentration mediated both by
passive permeability and active uptake through drug transporters. However, the major liver …

The organic anion transporting polypeptide (OATP) 2B1 is considered an emerging drug
transporter that is found expressed in pharmacokinetically relevant organs such as the liver …

Oatp inhibitors have been shown to significantly increase the plasma exposure of statins.
However, understanding alterations of liver concentration is also important. While modeling …